Zhitong Finance App News, Dongcheng Pharmaceutical (002675.SZ) announced that the company's holding subsidiary, Yantai Lanacheng Biotechnology Co., Ltd. (“Lan Nacheng”), has received a drug clinical trial approval notice approved by the China National Drug Administration on the drug clinical trial approval notice for ¹ Lu-LNC1010 injection and will conduct clinical trials in the near future.

According to reports, the product being developed by the company is a radiotherapy drug targeting somatostatin receptor 2 in vivo, and is suitable for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs) positive for somatostatin receptor 2 (SSTR2).